Elysium Therapeutics, Inc. is addressing development of a new class of opioid pain relievers designed to protect individuals from oral misuse, abuse and fatal overdose. Principals oft the firm are working on creation of a new class of opioid pain relievers that protect individuals from oral misuse, abuse, and fatal overdose from simultaneous ingestion of multiple pills. The firm reports progress towards development of its O2P (oral overdose protection) chemistry, designed to prevent opioid levels in the bloodstream from exceeding certain parameters. This mechanism serves to minimize addiction and side effects, making it an attractive approach to effective pain control.
